Collegium Completes $650M AZSTARYS Acquisition, Raises 2026 Guidance

Collegium Pharmaceutical has successfully completed its acquisition of AZSTARYS®, an attention-deficit/hyperactivity disorder (ADHD) treatment, from Corium Therapeutics for approximately $650 million. The transaction marks a significant strategic expansion for the specialty pharmaceutical company and immediately accretive to earnings, while the company simultaneously raised its financial outlook for 2026, signaling strong confidence in the combined entity's revenue-generating potential and operational efficiency.

Strategic Acquisition and Financial Details

The completion of the AZSTARYS acquisition represents a meaningful addition to Collegium's commercial portfolio, which has historically focused on pain management and neurology therapeutics. The transaction includes substantial intellectual property protections, with patent coverage extending through 2037, providing a substantial runway for revenue generation and market exclusivity.

Following the deal's closure, Collegium raised its 2026 financial guidance significantly:

• Total product revenues: Projected between $865 million and $895 million, representing substantial year-over-year growth
• Adjusted EBITDA: Expected to reach $475 million to $500 million, reflecting operational leverage and margin expansion
• Annual synergies: Expected to exceed $50 million through integration efficiencies and combined operations

The fact that the acquisition is immediately accretive to earnings underscores the underlying financial strength of AZSTARYS as a revenue contributor. The drug has established commercial traction in the competitive ADHD market, and Collegium's ability to integrate the asset while delivering synergies demonstrates disciplined capital allocation and operational execution.

Market Context: ADHD Therapeutics Landscape

The acquisition occurs within a robust and competitive ADHD pharmaceutical market. Attention-deficit disorders represent one of the largest mental health treatment categories globally, with millions of diagnosed patients seeking effective treatment options. The market has seen significant innovation in recent years, with both branded and generic competitors vying for market share.

AZSTARYS competes in a field populated by established players and newer entrants. The ADHD treatment space has attracted considerable pharmaceutical attention due to:

• Growing diagnosis rates: Increased recognition and screening of ADHD across age groups
• Prescription volume: Sustained demand for stimulant and non-stimulant treatments
• Premium pricing: Branded ADHD medications command favorable reimbursement profiles
• Patent-protected advantage: Extended exclusivity periods provide pricing power and competitive moats

For Collegium, the AZSTARYS acquisition diversifies its revenue base beyond its traditional pain management franchise, reducing reliance on any single therapeutic area. This diversification is particularly valuable given the evolving regulatory and payer landscape for opioid-related pain medications, which have faced increasing scrutiny and reimbursement pressures.

Investor Implications: Growth and Profitability

The raised guidance for 2026 carries significant implications for shareholders of Collegium ($COLL). The company's projection of $865-$895 million in total product revenues and $475-$500 million in adjusted EBITDA suggests a business capable of generating substantial operating cash flow—critical for a specialty pharmaceutical company.

Several factors make this acquisition particularly attractive from an investment perspective:

Immediate accretion: Unlike many pharmaceutical acquisitions that require years of integration before contributing to earnings, AZSTARYS is generating positive cash flow immediately, reducing execution risk and validating the purchase price.

Synergy realization: The $50+ million in expected annual synergies indicate management's ability to identify and capture efficiencies—whether through combined sales forces, elimination of duplicate functions, or optimized manufacturing and distribution.

Patent-protected revenue stream: The patent protection through 2037 ensures at least 13 years of exclusivity from the acquisition date, providing revenue visibility and protecting against generic erosion during a critical growth window.

EBITDA margin expansion: The guidance implies adjusted EBITDA margins of approximately 54-56% on projected revenues, indicating a highly profitable business model that generates substantial cash returns for shareholders.

For equity investors, this represents a company executing a classic specialty pharma growth strategy—deploying capital to acquire established, profitable commercial assets with strong intellectual property protection. The immediate accretion and visible synergies reduce the risk profile typically associated with acquisition-driven growth.

For credit investors and debt holders, the improved financial profile supports debt service capabilities and provides cushion for the leverage used to fund the transaction. The elevated EBITDA guidance suggests Collegium will have meaningful flexibility to optimize its capital structure.

Looking Forward

The successful completion of the AZSTARYS acquisition and raised 2026 guidance position Collegium as an increasingly diversified specialty pharmaceutical company with a clearer path to sustainable profitability. The company has demonstrated its ability to identify valuable assets, execute transactions, and integrate them efficiently—capabilities that shareholders will monitor as potential drivers of future value creation.

The expanded revenue base and improved profitability metrics provide a stronger foundation for organic R&D investments and potential future acquisitions. However, investors should remain cognizant of the inherent risks in the pharmaceutical industry, including regulatory changes, competitive pressures in ADHD treatment, patent litigation, and payer reimbursement dynamics.

The $650 million investment in AZSTARYS reflects management's confidence in the asset's long-term commercial viability and their ability to drive shareholder value through disciplined capital deployment.